MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis

Area of Science:

• Cancer Biology
• Metabolic Pathways
• Oncology

Background:

• Monocarboxylate transporters (MCTs) are implicated in cancer glycolysis and acidosis adaptation.
• The specific role of MCTs in gastric cancer (GC) remains incompletely understood.
• Investigating MCTs offers potential for novel GC therapeutic strategies.

Purpose of the Study:

• To characterize MCT isoforms 1, 2, and 4 expression in GC.
• To evaluate the therapeutic potential of targeting MCTs in GC.
• To determine MCT4's role in GC with peritoneal carcinomatosis.

Main Methods:

• Expression analysis of MCT1, MCT2, and MCT4 in GC cell lines and tissues.
• In vitro studies using siRNA to inhibit MCTs in GC cells.
• In vivo xenograft models to assess the impact of MCT inhibition on tumor growth.
• Assessment of GC cell sensitivity to radiotherapy and chemotherapy upon MCT inhibition.

Main Results:

• MCT1, MCT2, and MCT4 were upregulated in GC cell lines, with MCT1 and MCT4 being more prevalent.
• Inhibition of MCTs reduced GC cell viability, lactate uptake, and tumor growth in vivo.
• MCT4 was significantly overexpressed in GC tissues and malignant ascites cells.
• Silencing MCT4 decreased proliferation and lactate uptake in malignant ascites.

Conclusions:

• MCT4 is a clinically relevant therapeutic target in gastric cancer, especially in cases of peritoneal carcinomatosis.
• Targeting MCTs can enhance the efficacy of conventional therapies like radiotherapy and chemotherapy.
• MCT4 inhibition presents a promising strategy for gastric cancer treatment.